What Is Niagen Bioscience, Inc. (NAGE) Worth in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Niagen Bioscience, Inc.'s intrinsic value is estimated at $2.56, suggesting the stock is overvalued at its current price of $3.47. With 10 out of 12 models flagging downside (-26.2% average return), the market may be pricing in unsustainable growth. Notably, First Chicago sees the most upside at +107.9% (fair value: $7.21), while Dynamic NAV is the most conservative at -66.9% ($1.15). The spread between these extremes — +174.7% — reveals how different analytical frameworks can reach starkly different conclusions.
What Do the Models Say About NAGE?
12 of 13 models are currently active for NAGE. Of these, 1 model suggests upside while 11 models suggest overvaluation. The Bayesian DCF estimates NAGE's intrinsic value at $2.30, implying -33.6% downside from the current price. See which stocks rank higher →
How Does NAGE Rank in Medicinal Chemicals & Botanical Products?
Among 17 Medicinal Chemicals & Botanical Products stocks, NAGE ranks #1 by Quality of Company score. CirclFi's QOC score of 9.2/10 evaluates 32 fundamental signals. A score of 9.2 places NAGE in the top tier.
Within the Medicinal Chemicals & Botanical Products space, Niagen Bioscience, Inc. competes in an environment where aftermarket revenue mix often separates market leaders from laggards. Understanding these industry-specific dynamics is essential context for interpreting our model outputs.
Is NAGE a Value Trap?
CirclFi's Value Trap algorithm assigns NAGE a score of 12/100 (SAFE). This indicates minimal risk. Fundamentals are healthy. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →
Multi-Model Methodology
12 of 13 models are active for Niagen Bioscience, Inc.. Broad coverage provides high confidence. Each model applies a fundamentally different valuation philosophy. See the complete methodology →
According to the CirclFi Quality of Company (QOC) framework, which evaluates 32 signals including margin stability, revenue growth trajectory, leverage, and free cash flow generation, Niagen Bioscience, Inc. is rated at 9.2/10. This elite-tier score ranks among the highest-quality businesses in our coverage universe.
The gap between the most bullish and bearish model spans +174.7% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →
Data Sources & Confidence
Every NAGE valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →
Across NAGE's 12 active models, average confidence is 45%. Lower confidence may reflect limited history or high volatility.
CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →
Buy with Gumroad